Susquehanna International Group, LLP Akari Therapeutics PLC Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019
SELL
$1.89 - $4.01 $40,415 - $85,749
-21,384 Closed
0 $0
Q1 2019

May 15, 2019
SELL
$1.66 - $5.9 $10,434 - $37,087
-6,286 Reduced 22.72%
21,384 $77,000
Q4 2018

Feb 14, 2019
BUY
$1.57 - $2.49 $43,441 - $68,898
27,670 New
27,670 $43,000

About Akari Therapeutics Plc

AKTX Quotes by TradingView
  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $145M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email